Correction to Samsung Drug Story
24 July 2017 - 11:30PM
Dow Jones News
The Samsung-developed drug will be marketed to healthcare
providers by Merck & Co.'s U.S. sales team and will be sold for
about a 35% discount off of Remicade's current list price. "Samsung
Releases Lower-Cost Alternative to Johnson & Johnson's Drug
Remicade ," at 8:21 a.m. ET, incorrectly stated that the drug will
be sold for about 35% of Remicade's price. in the second
paragraph.
(END) Dow Jones Newswires
July 24, 2017 09:15 ET (13:15 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Samsung Electronics (PK) (USOTC:SSNHZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Samsung Electronics (PK) (USOTC:SSNHZ)
Historical Stock Chart
From Apr 2023 to Apr 2024